New Discovery May Predict Who Benefits From Cancer Treatment

Scientists just cracked a major puzzle in cancer treatment: why some patients thrive on immunotherapy while others don't respond at all.

Researchers at the Icahn School of Medicine at Mount Sinai identified a specific type of immune cell that plays a surprising and crucial role in fighting cancer. These cells, called IgG1 plasma cells, produce antibodies that help coordinate a powerful attack on tumors when patients receive PD-1 immunotherapy.

The discovery challenges what doctors thought they knew about how these treatments work. For years, immunotherapy was believed to work exclusively through T cells. Now it turns out antibody-producing cells are just as important in the fight.

The research team studied 38 liver cancer patients who received immunotherapy before surgery. When they examined tumor and blood samples, a clear pattern emerged. Patients whose tumors shrank had significantly more IgG1 plasma cells, especially during treatment.

These weren't random immune cells floating around. They were specialized clones that recognized specific proteins found almost exclusively in cancer cells, not healthy tissue. Blood tests revealed that successful responders had antibodies targeting these cancer proteins, and their T cells were also more active against tumors.

To confirm their findings weren't a fluke, researchers analyzed data from seven additional clinical trials involving more than 500 patients with different cancer types. They then checked survival data from over 1,500 additional patients in public databases. The pattern held strong: IgG1 plasma cells predicted better outcomes only in patients receiving immunotherapy, not standard treatments.

The Ripple Effect

This discovery could transform how doctors approach cancer care in multiple ways. First, testing for IgG1 plasma cells could become a simple blood test to predict which patients are most likely to benefit from immunotherapy before they even start treatment.

Second, it opens exciting possibilities for combination therapies. Cancer vaccines designed to boost these antibody responses alongside immunotherapy could make treatments work for more patients. The research team is already exploring this approach.

Perhaps most importantly, this knowledge could spare patients from treatments unlikely to help them. Immunotherapy can cause serious side effects and costs hundreds of thousands of dollars. Knowing in advance who will benefit means fewer people enduring difficult treatments that won't work for them.

The Mount Sinai team is now studying whether this immune response works the same way in blood cancers like multiple myeloma. They're also investigating how antibodies in the blood relate to plasma cells inside tumors, which could reveal even more about orchestrating effective immune responses.

The future of cancer treatment isn't just about finding more powerful drugs but understanding exactly how our immune system fights back and learning to work with it instead of around it.